Biocon Biologics Limited
CIN: U24119KA2016PLC093936
Biocon House, Tower-3,
Semicon Park Electronic City, Phase - II,
Hosur Road, Bengaluru, Karnataka 560100 IN
T +91 080-6775 6775, **F** +91 080-6775 1030
E contact@bioconbiologics.com
www.bioconbiologics.com

April 26, 2025

Singapore Exchange Securities Trading Limited
4 Shenton Way # 02-01
SGX Centre 2 Singapore 068807

Dear Sir/Madam,

Subject: Company Statement

Please find enclosed the company statement titled "**Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe**".

Kindly take the same on record and acknowledge.

Thanking you

Your faithfully

For Biocon Biologics Limited

Akhilesh Nand

Digitally signed by Akhilesh Nand
Date: 2025.04.26 11:10:24 +05'30'

Akhilesh Nand
Company Secretary
Membership No. ACS 13669
Address: Biocon House, Semicon Park
Tower 3, Electronic City Phase 2, Hosur Road
Bengaluru, Karnataka

Encl: as above

Notification To Stock Exchange

COMPANY STATEMENT

Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe

Bengaluru, Karnataka, India, April 26, 2025

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued positive opinions recommending the approval of its denosumab biosimilars candidates for distinct therapeutic indications for bone health: *Vevzuo®* and *Denosumab BBL* (brand name is currently under approval).

The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited, an indirect wholly owned subsidiary of Biocon Biologics Ltd.

These recommendations follow a review of comprehensive data packages, including clinical studies results[1], which demonstrated comparability with the reference product in terms of pharmacokinetic, safety, efficacy and immunogenicity profiles.

The European Commission will review the CHMP opinions and, following its decision, detailed information on the approved indications and usage will be included into the Summary of Product Characteristics (SmPCs), and the European Public Assessment Reports (EPARs), available in all official European Union languages.

Until marketing authorisations are granted by the European Commission, these products are not approved for use in the European Union.

– Company Spokesperson

[1] Anna Strzelecka, Grzegorz Kania, Pawan Kumar Singh, Kuldeep Kumar, Binay Kumar Thakur, Ashwani Marwah, Sudipta Basu, Nitin Madhukar Chaudhari, Sarika S Deodhar, Elena Wolff-Holz, Sandeep Nilkanth Athalye, Subramanian Loganathan. A Randomized, Double-blind, Multicenter, Parallel-arm Phase 3 Study to Compare the Efficacy, Pharmacodynamics, Safety, and Immunogenicity between Bmab-1000 and Prolia in Postmenopausal Women with Osteoporosis. Poster presented at ACR Congress 2024

R. Eastell, E. Orwoll, F. Cosman, A. Strzelecka, G. Kania, R. Plebanski, A. Mansukhbhai Ranpura, K. Kumar, B. Kumar Thakur, A. Marwah, S. Basu, N. Madhukar Chaudhari, S. S Deodhar, E. Wolff-Holz, S. Loganathan. Equivalence Trial of Proposed Denosumab Biosimilar Bmab-1000 And Reference Denosumab In Postmenopausal Osteoporosis: The Devote Study. Poster presented at WCO-IEF-ESCEO 2025